<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04936984</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-023</org_study_id>
    <nct_id>NCT04936984</nct_id>
  </id_info>
  <brief_title>Study to Evaluate and Compare the Bioequivalence of Two Abaloparatide-sMTS Treatments in Healthy Women.</brief_title>
  <official_title>An Open-Label, Randomized, 4-Period Crossover Study Evaluating the Bioequivalence of Two Abaloparatide-sMTS Treatments and the Effect of Small Variations in Wear-Time in Healthy Women.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to evaluate the bioequivalence of abaloparatide between 2 abaloparatide-sMTS&#xD;
      treatments 300 μg treatments applied to the thigh for 5 minutes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single site, open-label, randomized, 4-period crossover study to evaluate the&#xD;
      bioequivalence of 2 abaloparatide-sMTS 300 μg treatments (Patheon sterile abaloparatide-sMTS&#xD;
      and Kindeva ultra-low bioburden abaloparatide-sMTS) applied to the thigh for 5 minutes. The&#xD;
      study will also evaluate the effect of small deviations in the wear-time of the Patheon&#xD;
      abaloparatide-sMTS worn for 4 minutes or 7 minutes compared to the Patheon abaloparatide-sMTS&#xD;
      worn for the prescribed 5 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Actual">February 9, 2021</completion_date>
  <primary_completion_date type="Actual">February 9, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>All subjects were to receive a transdermal patch containing 300 μg abaloparatide for 4,5 and 7 minutes in 4 separate periods.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax)</measure>
    <time_frame>4 single-dose administrations, separated by 48 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC 0-t)</measure>
    <time_frame>4 single-dose administrations, separated by 48 hours.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC from time 0 extrapolated to time infinity (AUC 0-∞)</measure>
    <time_frame>4 single-dose administrations, separated by 48 hours.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects with treatment-emergent AEs and SAEs</measure>
    <time_frame>14 ± 2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abaloparatide-sMTS is a drug-device combination product consisting of abaloparatide coated onto a microstructure array for transdermal administration of abaloparatide. The abaloparatide-sMTS is manufactured at Patheon (sterile environment) or Kindeva (low bioburden environment).</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-sMTS (Patheon)</intervention_name>
    <description>single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes</description>
    <arm_group_label>Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min</arm_group_label>
    <arm_group_label>Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min</arm_group_label>
    <arm_group_label>Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min</arm_group_label>
    <arm_group_label>Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min</arm_group_label>
    <other_name>abaloparatide-sMTS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-sMTS (Kindeva)</intervention_name>
    <description>single-dose administration of abaloparatide 300 μg applied to the thigh for 5 minutes</description>
    <arm_group_label>Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min</arm_group_label>
    <arm_group_label>Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min</arm_group_label>
    <arm_group_label>Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min</arm_group_label>
    <arm_group_label>Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min</arm_group_label>
    <other_name>abaloparatide-sMTS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-sMTS (Patheon)</intervention_name>
    <description>single-dose administration of abaloparatide 300 μg applied to the thigh for 4 minutes</description>
    <arm_group_label>Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min</arm_group_label>
    <arm_group_label>Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min</arm_group_label>
    <arm_group_label>Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min</arm_group_label>
    <arm_group_label>Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min</arm_group_label>
    <other_name>abaloparatide-sMTS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>abaloparatide-sMTS (Patheon)</intervention_name>
    <description>single-dose administration of abaloparatide 300 μg applied to the thigh for 7 minutes</description>
    <arm_group_label>Kindeva sMTS 5 min, then Patheon sMTS 7 min, then Patheon sMTS 5 min, then Patheon sMTS 4 min</arm_group_label>
    <arm_group_label>Patheon sMTS 4 min, then Patheon sMTS 5 min, then Patheon sMTS 7 min, then Kindeva sMTS 5 min</arm_group_label>
    <arm_group_label>Patheon sMTS 5 min, then by Kindeva sMTS 5 min, then Patheon sMTS 4 min, then Patheon sMTS 7 min</arm_group_label>
    <arm_group_label>Patheon sMTS 7 min, then Patheon sMTS 4 min, then Kindeva sMTS 5 min, then Patheon sMTS 5 min</arm_group_label>
    <other_name>abaloparatide-sMTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female subjects aged 40 to 65 years old, inclusive, at Screening&#xD;
&#xD;
          -  Good general health as determined by medical history and physical exam (including&#xD;
             vital signs, and has a body mass index between 18 and 34 kg/m^2 inclusive)&#xD;
&#xD;
          -  Laboratory tests within the normal range&#xD;
&#xD;
          -  Serum 25-hydroxyvitamin D values must be &gt; 20 ng/mL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence or history of any disorder that may prevent the successful completion of the&#xD;
             study.&#xD;
&#xD;
          -  Diagnosed with osteoporosis, Paget's disease, or other metabolic bone diseases (eg,&#xD;
             vitamin D deficiency or osteomalacia), or had a non-traumatic fracture within 1 year&#xD;
             prior to the initial screening;&#xD;
&#xD;
          -  History of any cancer within the past 5 years other than squamous or basal cell&#xD;
             carcinoma;&#xD;
&#xD;
          -  History of allergy to abaloparatide or drugs in a similar pharmacological class;&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 16, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 23, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoporosis</keyword>
  <keyword>transdermal delivery</keyword>
  <keyword>microneedle patch</keyword>
  <keyword>solid microstructured transdermal system</keyword>
  <keyword>abaloparatide TYMLOS®</keyword>
  <keyword>abaloparatide-SC</keyword>
  <keyword>PK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abaloparatide</mesh_term>
    <mesh_term>Parathyroid Hormone-Related Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

